Omega Diagnostics Group (LON:ODX) Earns Corporate Rating from FinnCap

FinnCap reissued their corporate rating on shares of Omega Diagnostics Group (LON:ODX) in a research report report published on Monday morning, ThisIsMoney.Co.Uk reports.

LON:ODX opened at GBX 12 ($0.16) on Monday. The stock has a fifty day moving average price of GBX 10.05 and a 200-day moving average price of GBX 11.12. The company has a market cap of $16.00 million and a price-to-earnings ratio of -2.31. The company has a debt-to-equity ratio of 3.80, a quick ratio of 1.18 and a current ratio of 1.82. Omega Diagnostics Group has a fifty-two week low of GBX 8.19 ($0.11) and a fifty-two week high of GBX 18 ($0.24).

Omega Diagnostics Group Company Profile

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.

Featured Story: Why is the conference call important?

Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.